RubiconMD Secures $18M in Series C Financing Led by Deerfield Management Company

RubiconMD, the leading eConsult platform providing access to specialist expertise, today announced it raised $18 million in Series C funding led by Deerfield Management Company.

Also participating in this investment round are existing investors including Optum Ventures, HLM Venture Partners, Waterline Ventures and Heritage Provider Network. To date, the Company has raised more than $40 million.

As part of the financing round, RubiconMD is adding Julian Harris, M.D., Partner at Deerfield, to the Company’s Board of Directors. Trained as a primary care physician, Dr. Harris has played a key role in helping to accelerate the country’s shift towards value-based payment through senior roles in the public and private sector.

“We are at a crucial moment in the shift towards a value-based health care system, with private and public payers seeking to find innovative ways to improve quality and affordability,” Dr. Harris said. “By enabling primary care clinicians to practice at the top of their license, RubiconMD serves as a vital partner for the country’s most innovative primary care groups, helping them to improve outcomes for patients and to reduce costs for our system.”

Optum Ventures, who co-led the Company’s last round of funding, joined Deerfield in the current round. “By removing the barriers to receiving specialty insights in all settings of care, RubiconMD is driving healthcare towards a more accessible, value-based ecosystem,” said Laura Veroneau, Partner at Optum Ventures and Board member. “RubiconMD has seen remarkable growth and we are thrilled to continue partnering in their work to bring the healthcare industry into the future.”

Motivated by their own experiences within the healthcare system, CEO Gil Addo and President Carlos Reines founded RubiconMD in 2013 to bridge the gap between primary and specialty care. Today, the platform offers quick access to specialist insights across more than 120 specialties. The company has partnered with the top payors in the country to scale its offering.

“We are delighted to bring on Deerfield as an investor,” said Addo. “Deerfield’s experience, reach and commitment to realizing the future of healthcare will be pivotal as we continue to break down barriers to access and ensure all patient populations receive the care they need.”

The Company expects to use the new capital to fuel its ongoing growth. RubiconMD also plans to leverage its data to deliver new product offerings to better serve primary care clinicians. “Our goal has always been to empower primary care.” said Reines. “We remain focused on ensuring that the right information is delivered into the hands of the primary care clinician at the right time, so they are able to drive towards better, more efficient care delivery.”

 

SourceRubiconMD

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”